Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Axitinib + Pembrolizumab in Advanced RCC
NCT02133742Phase 1Completed
- Sponsor
- Pfizer
- Start
- Sep 2014
- Primary completion
- Mar 2017
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of axitinib and pembrolizumab in renal cell carcinoma (RCC), sponsored by Pfizer. Primary endpoint: Dose-Limiting Toxicities. Started Sep 2014; status: completed.
02
Drugs
axitinibpembrolizumab
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT02133742.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02133742.